Home Page Election 2019 News Opinion Foreign Policy Politics Policy Legislation Lobbying Hill Life & People Hill Climbers Heard On The Hill Calendar Archives Classifieds
Hill Times Events Inside Ottawa Directory Hill Times Store Hill Times Careers The Wire Report The Lobby Monitor Parliament Now
Subscribe Free Trial Reuse & Permissions Advertising
Log In
Policy Briefing: Biotech Policy Briefing
Among other findings, Deloitte statistics show that 45 per cent of Canadian biotechnology companies got funding from government programs in 2017, and of those, 80 per cent got funds through the Scientific Research and Experimental Development Program. Image courtesy of Pixabay
Open science partnerships are breaking the traditional pathways of research and development. While not a panacea, they pose a unique and exciting made-in-Canada solution to our pressing productivity challenges.
The full use of gene editing depends on whether it is able to garner wide-scale political and consumer support, which genetic modification technology has been unable to do.
Recent reports on the industry don't deal with issues like firm size and employee talent levels, which are crucial to understanding an evolving industry, says BIOTECanada's Andrew Casey.
There is a growing sector of innovators and entrepreneurs looking to revolutionize healthcare delivery. They need access to clinical data to develop new technologies.
Opinion|David Crane
At present, there is no discernible evidence of a cross-cutting or all-of-government strategy to increase the commercial dividends from the scientific capital we have accumulated in the biological sciences.
Canada can carve out some significant space in the innovation and entrepreneurship market of medical devices and health technology, provided we collectively decide to turn our focus there.

Your group subscription includes premium access to Politics This Morning briefing.